SR One, the independent venture arm of London-based drug giant GlaxoSmithKline (NYSE:[[ticker:GSK]]), has established a San Francisco office after a long history of backing West Coast biotechs such as Amgen (NASDAQ:[[ticker:AMGN]]) and Idec Pharmaceuticals (now part of Biogen Idec (NASDAQ:[[ticker:BIIB]]) of Weston, MA), the group announced today. Simeon George, a partner at SR One, is leading the venture group’s San Francisco office. SR One now has offices in London, Boston, Philadelphia, and San Francisco. Christoph Westphal, the president of SR One, is expected to leave his post at SR One later this year and is now a partner and founder at Boston-based venture firm Longwood Founders Fund.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
